Donor leukocyte infusion after allogeneic bone marrow transplantation was not effective for relapsed rhabdomyosarcoma

被引：0

作者：

H Moritake

Y Ikuno

H Tasaka

H Koga

S Miyazaki

J Okamura

机构：

[1] Section of Pediatrics,Department of Pediatrics

[2] National Kyushu Cancer Center,undefined

[3] Saga Medical College,undefined

来源：

Bone Marrow Transplantation | 1998年 / 21卷

关键词：

rhabdomyosarcoma; alloBMT; DLI;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A 10-year-old boy with metastatic rhabdomyosarcoma had an HLA-identical sibling and received an allogeneic BMT. Recurrence was detected in the BM as the only site of treatment failure 12 months after BMT. Donor leukocyte infusion (DLI) was chosen as salvage therapy. Although sufficient cells (a total of 29.7 × 107/kg) were infused, no signs of acute GVHD nor BM aplasia occurred and the patient died of disease progression 9 months after DLI.

引用

页码：725 / 726

页数：1

共 50 条

[1] Donor leukocyte infusion after allogeneic bone marrow transplantation was not effective for relapsed rhabdomyosarcoma
Moritake, H
Ikuno, Y
Tasaka, H
Koga, H
Miyazaki, S
Okamura, J
BONE MARROW TRANSPLANTATION, 1998, 21 (07) : 725 - 726
[2] Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
Lokhorst, HM
Schattenberg, A
Cornelissen, JJ
Thomas, LLM
Verdonck, LF
BLOOD, 1997, 90 (10) : 4206 - 4211
[3] Donor leukocyte infusion as salvage therapy in an adult with relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation
Chang, CS
Lin, SF
Liu, TC
Huang, SM
Chen, TP
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1998, 97 (01) : 55 - 58
[4] Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Indications and dose escalation
Shiobara, S
Nakao, S
Ueda, M
Yamazaki, H
Takahashi, S
Asano, S
Yabe, H
Kato, S
Imoto, S
Maruta, A
Yoshida, T
Gondo, H
Morishima, Y
Kodera, Y
THERAPEUTIC APHERESIS, 2001, 5 (01): : 40 - 45
[5] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
Collins, RH
Shpilberg, O
Drobyski, WR
Porter, DL
Giralt, S
Champlin, R
Goodman, SA
Wolff, SN
Hu, W
Verfaillie, C
List, A
Dalton, W
Ognoskie, N
Chetrit, A
Antin, JH
Nemunaitis, J
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 433 - 444
[6] Impact of donor lymphocyte infusion for hematological malignancy relapsed after allogeneic bone marrow transplantation
Zeder, K
Waller, EK
Redei, I
Connaghan, DG
Fleming, WH
Geller, RB
Heffner, LT
Hillyer, CD
Holden, J
Holland, K
Jones, W
Mccollum, J
Mogul, M
Phillips, C
Rodey, G
Wingard, JR
Winton, E
Yeager, AM
Devine, S
CANCER RESEARCH THERAPY & CONTROL, 1998, 5 (04): : 221 - 228
[7] Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation
Fores, R
DiezMartin, JL
Briz, M
Cabrera, JR
Sanjuan, I
Regidor, C
GarciaTalavera, J
Fernandez, MN
BONE MARROW TRANSPLANTATION, 1996, 17 (03) : 439 - 441
[8] Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program
Miyamoto, Toshihiro
Fukuda, Takahiro
Nakashima, Marie
Henzan, Tomoko
Kusakabe, Shinsuke
Kobayashi, Naoki
Sugita, Junichi
Mori, Takeshi
Kurokawa, Mineo
Mori, Shin-ichiro
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (06) : 938 - 944
[9] DONOR LEUKOCYTE INFUSIONS FOR CHRONIC MYELOID-LEUKEMIA RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
BAR, BMAM
SCHATTENBERG, A
MENSINK, EJBM
VANKESSEL, AG
SMETSERS, TFCM
KNOPS, GHJN
LINDERS, EHP
DEWITTE, T
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 513 - 519
[10] THE EFFECT OF DONOR LEUKOCYTE INFUSION IN PATIENTS WITH LEUKEMIA FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
FRASSONI, F
FAGIOLI, F
SESSAREGO, M
GUALANDI, F
VANLINT, MT
LAMPARELLI, T
OCCHINI, D
FIGARI, O
VALBONESI, M
BACIGALUPO, A
EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 712 - 712

← 1 2 3 4 5 →